Brief: Karolinska Development's Portfolio Company Raises SEK 23.8 Mln To Continue Development Of Golexanolone

Kdventures AB

19/12/2024 07:50

Dec 19 (Reuters) - Karolinska Development AB  KDEV.ST :
    * REG-KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY UMECRINE COGNITION RAISES MSEK 23.8 TO
CONTINUE
CLINICAL DEVELOPMENT OF GOLEXANOLONE

Source text:  ID:nGNE3VRrkM 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))